<DOC>
	<DOCNO>NCT01171170</DOCNO>
	<brief_summary>This study design assess effect add nitroglycerin ( NTG ) patch , delivery 25 mg NTG per 24 h , standard first line treatment metastatic non-squamous non-small cell lung cancer ( NSCLC ) , i.e . 4 cycle carboplatin-paclitaxel-bevacizumab , follow bevacizumab alone disease progression . Tumor hypoxia common phenomenon lung cancer ; know poor prognostic marker , related treatment resistance . Pre-clinical study show nitric oxide ( NO ) donate drug may decrease hypoxia relate drug resistance . NTG NO donate drug . NTG increase tumor blood flow thereby augments antitumor drug delivery tumor . A randomized phase II show increase response rate 42 % 72 % , NTG patch ( 25 mg/day , day -2 +3 ) add vinorelbine/cisplatin patient advance NSCLC . In addition , time progression increase 185 327 day . The hypothesis present study add NTG transdermal patch bevacizumab contain chemotherapy improve progression free survival , response rate overall survival patient metastatic non-squamous NSCLC .</brief_summary>
	<brief_title>Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin Metastatic Non-Squamous-Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Standard treatment non-small cell lung cancer ( NSCLC ) consist platinum-containing chemotherapy . It show addition bevacizumab standard chemotherapy improve progression-free survival ( PFS ) overall survival ( OS ) patient non-squamous NSCLC . There need improve PFS OS response rate chemotherapy 25-35 % . Tumor hypoxia common phenomenon lung cancer ; know poor prognostic marker , related treatment resistance . Hypoxia Inducible Factor ( HIF ) -1α major factor regulate response hypoxia . HIF directly activate vascular endothelial growth factor ( VEGF ) VEGF-receptor . Bevacizumab interact pathway block VEGF . Pre-clinical study show nitric oxide ( NO ) donate drug may decrease hypoxia relate drug resistance . Nitroglycerin ( NTG ) NO donate drug . NTG increase tumor blood flow thereby augments antitumor drug delivery tumor inhibit HIF-1α . Interestingly , recently show mouse model addition HIF-1α inhibitor bevacizumab significantly inhibits tumor growth induce apoptosis . A randomized phase II show increase response rate 42 % 72 % , NTG patch ( 25 mg/day , day -2 +3 ) add vinorelbine/cisplatin patient advance NSCLC . In addition , time progression increase 185 327 day . The hypothesis present study add NTG transdermal patch bevacizumab contain chemotherapy improve PFS , response rate OS patient metastatic non-squamous NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>Histologically/cytologically proven stage IV nonsquamous NSCLC ( accord IASLC stag 7.0 ) No prior chemotherapy therapy systemic antitumor therapy ( e.g. , monoclonal antibody therapy ) prior exposure agent direct HER axis ( e.g . epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ) , Herceptin ) . Prior surgery and/or localize palliative irradiation permit provide irradiated lesion measurable lesion . Prior adjuvant chemotherapy &gt; 1 year ago prior treatment EGFRTKI patient activate EGFR mutation allow . Age ≥ 18 year . ECOG Performance Status 0 2 . Life expectancy least 12 week . Subjects least one unidimensional ( RECIST ) measurable lesion . Adequate bone marrow , liver renal function . Adequate nonhormonal contraception female childbearing potential study 6 month thereafter . Adequate contraception male participant ( partner ) study 6 month thereafter . Clinically significant ( i.e . active ) cardiovascular disease : congestive heart failure &gt; NYHA class 2 ; CVA myocardial infarction &lt; 6 month prior study entry ; uncontrolled hypertension ( blood pressure systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) . Symptomatic hypotension . History hemoptysis least grade 2 ( bright red blood least 2,5 ml last 3 month ) Evidence tumor invade major blood vessel image ( i.e . superior vena cava pulmonary artery ) . History HIV infection chronic hepatitis B C. Active clinically serious infection Symptomatic metastatic brain meningeal tumor . Patients brain metastasis may include patient treat brain radiotherapy asymptomatic . History organ allograft . Patients evidence history bleed diathesis . Nonhealing wound ulcer . History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month enrolment Anticancer chemotherapy immunotherapy study within 4 week study entry Radiotherapy within 4 week start study drug . Palliative radiotherapy bone lesion allow &gt; 14 day start chemotherapy . Major surgery within 4 week start study . Use vasodilator ( include 5phosphodiesterase inhibitor , calcium antagonist nitrate ) Autologous bone marrow transplant stem cell rescue within 4 month study Investigational drug therapy outside trial within 4 week study entry Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>stage IV</keyword>
	<keyword>nitroglycerin</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>bevacizumab</keyword>
</DOC>